Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

BACKGROUND: On the basis of the DREAMM‐2 study (ClinicalTrials.gov identifier NCT03525678), single‐agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received ≥4 prior therapies, including anti‐CD38 therapy. The authors investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597112/
https://www.ncbi.nlm.nih.gov/pubmed/34314018
http://dx.doi.org/10.1002/cncr.33809

Ejemplares similares

Ejemplares similares